Literature DB >> 10320451

Assessment and Management of "Sundowning" Phenomena.

.   

Abstract

Approximately one quarter of patients with AD-type dementia reportedly exhibit disruptive, restless, and/or confused behavior that tends to be more apparent in late afternoon or early evening. Research has yet to document the phenomenon in a definitive manner to facilitate standardized assessment and clinical trials. Recent work attempting to define precisely the prevalence of abnormal behaviors during different periods of time of day in AD patients is reviewed. Caregiver reports of confusion and aggressive, disruptive behavior have been associated with going to bed early, increased use of sedative-hypnotics, and more severe cognitive impairment. Because there is evidence that the sleep of many AD patients is of poor quality, one might try to treat such patients with behavioral approaches useful in insomnia in other populations. Futhermore, as psychotropic medications can adversely affect sleep and/or have "hangover" effects on daytime cognition, one should carefully manage these medications to optimize care. Advances in assessment of sundowning, combined with longitudinal studies of sleep and circadian rhythm changes associated with dementia progression, should enhance efforts to treat behavioral and sleep disturbances.

Entities:  

Year:  1997        PMID: 10320451     DOI: 10.1053/SCNP00200113

Source DB:  PubMed          Journal:  Semin Clin Neuropsychiatry        ISSN: 1084-3612


  6 in total

1.  Incidence and risk factors of workplace violence on psychiatric staff.

Authors:  Marilyn Ridenour; Marilyn Lanza; Scott Hendricks; Dan Hartley; Jill Rierdan; Robert Zeiss; Harlan Amandus
Journal:  Work       Date:  2015

Review 2.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei.

Authors:  Analía M Furio; Rodolfo A Cutrera; Víctor Castillo Thea; Santiago Pérez Lloret; Patricia Riccio; Roberto L Caccuri; Luis L Brusco; Daniel P Cardinali
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

Review 4.  Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment.

Authors:  M V Vitiello; S Borson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Clinical aspects of melatonin intervention in Alzheimer's disease progression.

Authors:  Daniel P Cardinali; Analía M Furio; Luis I Brusco
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

6.  Melatonin in Alzheimer's disease and other neurodegenerative disorders.

Authors:  V Srinivasan; S R Pandi-Perumal; D P Cardinali; B Poeggeler; R Hardeland
Journal:  Behav Brain Funct       Date:  2006-05-04       Impact factor: 3.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.